TheraRadar
← Back
Data updated: Jul 17, 2026

MEDPOINTE PHARM HLC

Specialty
Pharmaceuticals

MEDPOINTE PHARM HLC is a specialty pharmaceutical company with 18 FDA-approved products.

1955
Since
18
Drugs
-
Trials
0
New Drugs (2yr)

MEDPOINTE PHARM HLC's Key Drugs

MEDPOINTE PHARM HLC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MEDPOINTE PHARM HLC's Recent FDA Approvals

New NDA/BLA approvals for MEDPOINTE PHARM HLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MEDPOINTE PHARM HLC's Therapeutic Areas

Disease areas where MEDPOINTE PHARM HLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MEDPOINTE PHARM HLC Pipeline Snapshot

Active clinical trials for MEDPOINTE PHARM HLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling